Subsequent Events

9 Months Ended

Jun. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

17. Subsequent Event

On July 22, 2021, the Company signed a definitive agreement to acquire from Otsuka America Pharmaceutical, Inc. (“OAPI”) its BreathTek® business in the U.S. and Mexico for $20,000 in cash. BreathTek is an FDA approved urea breath test for the detection of H. pylori. Assets to be acquired include test kit inventory, customer relationships and rights to the BreathTek trade name. In addition, the Company and OAPI have entered into a transition services agreement, which is designed to allow the Company to integrate the BreathTek business in a manner that provides appropriate customer support. This transaction closed on July 31, 2021. The purchase price was funded with cash and cash equivalents on hand and this acquisition will be included in our Diagnostics segment.